In this episode, we review recommendations 73 to 84 from the 2025 American Thyroid Association guidelines on managing radioiodine refractory differentiated thyroid cancer and survivorship care.
Key topics include:

• Use of immunotherapy, redifferentiation therapy, and local or systemic treatments for advanced disease.

• Pregnancy management, including timing of surgery, imaging considerations, and TSH goals.

• Long term follow up focusing on side effect monitoring, financial counseling, and psychosocial support.